Lipid-lowering Dispersible Tablet on Rats with Hyperlipidemia Fatty Liver Effects

[Objective]To observe lipid-lowering dispersible tablet on rats with hyperlipidemia fatty liver effects.[Methods]60 Wistar rats weighing order code according to the original number,check table of random numbers were randomly divided into control group,model group,lipid-lowering dispersible tablets group(low 0.22g/kg,0.66g/kg,1.32g/kg dose group),Zhibituo positive drug group.Each group of 10,male and female half,divided cage rearing,each cage 5.Blank control group,model group gavage in distilled water,the drug group gavage corresponding drug;blank control group fed with common feed,the other groups were fed a high fat diet made in rat fatty liver model,was administered for eighth weeks of detection of serum total cholesterol(TC),triglyceride(TG),alanine aminotransferase(ALT),aspartate aminotransferase(AST) and liver tissues of free fatty acid(FFA),malondialdehyde(MDA),superoxide dismutase(SOD),glutathione peroxidase(GSH-Px).[Results]Lipid-lowering dispersible tablets in a dose-dependent manner: reduce fatty liver model rats serum TC,TG,ALT,FFA,AST and liver MDA content(P0.01),significantly improve the fatty liver model of rat SOD,GSH-Px activity(P0.01).[Conclusion]Lipid-lowering dispersible tablet on rats with hyperlipidemia fatty liver effects showed a dose-effect relationship,can inhibit liver steatosis of liver lipid metabolism disorders,reduce the damage of liver cell,improve the antioxidant ability of liver tissue.